RGD Reference Report - FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma.

Authors: Ge, Jun  Jiang, Li  Tian, Yuke  Zheng, Min  Huang, Meiling  Li, Juan 
Citation: Ge J, etal., J Int Med Res. 2020 Apr;48(4):300060520919252. doi: 10.1177/0300060520919252.
RGD ID: 151667913
Pubmed: PMID:32517588   (View Abstract at PubMed)
PMCID: PMC7218937   (View Article at PubMed Central)
DOI: DOI:10.1177/0300060520919252   (Journal Full-text)


OBJECTIVES: This study aimed to explore the expression profile of the Forkhead box protein L2 gene (FOXL2) and to determine its prognostic value and associated epigenetic and genetic alterations in patients with laryngeal squamous cell carcinoma (LSCC).
MATERIALS AND METHODS: Data for a subset of patients with LSCC (N = 116) were extracted from the head and neck squamous cell carcinoma dataset of The Cancer Genome Atlas and analyzed in relation to FOXL2 expression and survival.
RESULTS: Aberrant FOXL2 expression was an independent prognostic factor for progression-free survival (PFS) (hazard ratio (HR): 2.63, 95% confidence interval (CI): 1.34-5.18) and overall survival (OS) (HR: 2.39, 95%CI: 1.28-4.46). Two gene-body CpG sites (cg10554436 and cg23637494) were moderately and positively correlated with FOXL2 expression. DNA amplification (+2/+1) was common (82/115, 71%) in LSCC, and FOXL2 expression was significantly upregulated in the high-amplification group (+2) compared with copy-neutral (0) cases.
CONCLUSION: Aberrant FOXL2 expression may be a novel prognostic biomarker for PFS and OS among patients with LSCC. FOXL2 upregulation may be related to gene-body hypermethylation and DNA amplification.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
laryngeal squamous cell carcinoma exacerbatesIEP 151667913mRNA:increased expression:larynx (human)RGD 
laryngeal squamous cell carcinoma exacerbatesISOFOXL2 (Homo sapiens)151667913; 151667913mRNA:increased expression:larynx (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Foxl2  (forkhead box L2)

Genes (Mus musculus)
Foxl2  (forkhead box L2)

Genes (Homo sapiens)
FOXL2  (forkhead box L2)


Additional Information